Chemical compounds

Abstract

The present invention discloses compounds of Formula I. The present invention also discloses beta-3 agonists of formula I and methods for treating beta-3 mediated diseases and condition using the compounds of formula I, in particular methods for treating diabetes or obesity.

1 . A method for the prevention or treatment of clinical conditions or diseases susceptible to amelioration by administration of an atypical beta-adrenoceptor agonist, comprising administration of an effective amount of a compound of formula (I), or a pharmaceutically acceptable derivative thereof:  
     
       
         
         
             
             
         
       
     
     wherein X is oxygen or sulfur, and where the heterocycle containing X is substituted meta or para to the depicted NH; 
 R 1  is hydrogen or C 1-6 alkyl;  
 R represents substituents selected from C 1-6  alkyl, halogen, trifluoromethyl, and  
 C 1-6 alkoxy; and  
 n represents an integer from  0-4.    
 
   
   
       2 . The method of  claim 1  wherein said condition or disease is obesity.  
   
   
       3 . The method of  claim 1  wherein said condition or disease is urinary incontinence.  
   
   
       4 . A method for the prevention or treatment of obesity comprising administration of an effective amount of a compound selected from: 
   2-( 3-{2R-[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]propylamino}phenyl)furan-3-carboxylic acid;      2-( 3-{[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]ethylamino}phenyl)furan-3-carboxylic acid;      2-( 4-{2R-[2-(3-Chlorophenyl)-2R-hydroxylethylamino]propylamino}phenyl)furan-3-carboxylic acid;    2-(3-{2R-[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]propylamino}phenyl)thiophene-3-carboxylic acid;      2-( 3-{[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]ethylamino)phenyl)thiophene-3-carboxylic acid;      2-( 4-{2R-[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]propylamino}phenyl)thiophene-3-carboxylic acid;    or pharmaceutically acceptable derivatives thereof.    
   
   
       5 . The method of  claim 4  wherein the compound is selected from 2-(3-{[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]ethylamino}phenyl)furan-3-carboxylic acid; 
   2-( 3-{[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]ethylamino}phenyl)thiophene-3-carboxylic acid;    or pharmaceutically acceptable derivatives thereof.    
   
   
       6 . A method for the prevention or treatment of urinary incontinence comprising administration of an effective amount of a compound selected from: 
   2-( 3-{2R-[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]propylamino}phenyl)furan-3-carboxylic acid;      2-( 3-{[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]ethylamino}phenyl)furan-3-carboxylic acid;      2-( 4-{2R-[2-(3-Chlorophenyl)-2R-hydroxylethylamino]propylamino}phenyl)furan-3-carboxylic acid;      2-( 3-{2R-[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]propylamino}phenyl)thiophene-3-carboxylic acid;      2-( 3-{[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]ethylamino}phenyl)thiophene-3-carboxylic acid;      2-( 4-{2R-[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]propylamino}phenyl)thiophene-3-carboxylic acid;    or pharmaceutically acceptable derivatives thereof.    
   
   
       7 . The method of  claim 6  wherein the compound is selected from 2-(3-{[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]ethylamino}phenyl)furan-3-carboxylic acid; 
   2-( 3-{[2-(3-Chlorophenyl)-2R-hydroxyl-ethylamino]ethylamino}phenyl)thiophene-3-carboxylic acid;    or pharmaceutically acceptable derivatives thereof.